Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26/MVA Therapeutic Vaccine for HPV16/18 Infection
NCT03610581Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2018
- Primary completion
- Oct 2020
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of adenovirus serotype 26-expressing HPV16 vaccine, adenovirus serotype 26-expressing HPV18 vaccine and JNJ-65195208 in human papillomavirus infection (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Solicited Local Adverse Events, Number of Participants With Solicited Systemic Adverse Events and 2 more. Started Sep 2018; status: terminated.
02
Drugs
adenovirus serotype 26-expressing HPV16 vaccineadenovirus serotype 26-expressing HPV18 vaccineJNJ-65195208
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03610581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610581.